CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02909452
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:19.987794+00:00
Published At: 2022-01-25T00:00:00+00:00
Record Updated At: 2022-01-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Neoplasms", "Neoplasms, Glandular and Epithelial", "Neoplasms by Histologic Type", "Bronchial Neoplasms", "Lung Neoplasms", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Digestive System Neoplasms", "Endocrine Gland Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Lung Diseases", "Breast Diseases", "Renal Neoplasm", "Solid Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-01-25"
protocolSection.identificationModule.nctId: "NCT02909452"
protocolSection.identificationModule.officialTitle: "A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.